Last updated: July 19, 2026
Teva v. Mylan (1:17-cv-01790) Litigation Summary and Patent/Strategy Analysis
Teva Pharmaceuticals International GmbH sued Mylan Laboratories Limited in the U.S. District Court under docket 1:17-cv-01790, alleging infringement tied to Teva’s protected product. The record of this case name and docket exists, but the litigation outcome, asserted patents, FDA filing details (including whether it was an ANDA with a Paragraph IV), settlement terms, and court rulings are not provided in the available information here. Without those case-specific facts, a complete and accurate patent-and-procedure analysis cannot be produced.
What patents were asserted in Teva v. Mylan Laboratories Limited 1:17-cv-01790?
No asserted-patent list, patent numbers, or claims-by-claim mapping is included in the available inputs.
Which Teva patents were allegedly infringed?
Not provided.
What Orange Book patents were implicated?
Not provided.
Were method-of-use patents, formulation patents, or manufacturing-method patents at issue?
Not provided.
Was this case an ANDA Paragraph IV challenge, a Section 505(b)(2) dispute, or another Hatch-Waxman vehicle?
The litigation vehicle (e.g., ANDA with Paragraph IV certification under 21 U.S.C. § 355(j)(2)(A)-(D), Section 505(b)(2), or a non-Hatch-Waxman theory) is not included in the available inputs.
Did the complaint cite FDA certifications (4(A), 4(B), 4(C), 4(D))?
Not provided.
What was Mylan’s proposed drug and dosage form?
Not provided.
What did the court decide in Teva v. Mylan 1:17-cv-01790?
No procedural posture is supplied: no motion rulings, claim construction results, infringement/non-infringement findings, validity outcomes, or final judgment is included in the available inputs.
Were there Markman (claim construction) rulings?
Not provided.
Were there summary judgment decisions on validity or infringement?
Not provided.
Did the case end in judgment, dismissal, or a consent settlement?
Not provided.
What settlements or license terms resolved Teva v. Mylan 1:17-cv-01790?
No settlement date, agreement structure, exclusivity carveouts, launch dates, or payment-for-delay terms are provided in the available inputs.
Did Teva and Mylan enter a stipulation of dismissal?
Not provided.
Did the settlement include a “carve-out” for specific patents or strengths?
Not provided.
Were there stipulated design-arounds or product-label constraints?
Not provided.
What is the infringement and validity posture implied by Teva v. Mylan 1:17-cv-01790?
No asserted-patent numbers, trial record, expert issues, or validity grounds are included, so analysis of obviousness, written description, enablement, indefiniteness, or prosecution history estoppel cannot be performed accurately.
Which validity defenses were raised?
Not provided.
What technology arguments were made (process, composition, bioequivalence, metrics)?
Not provided.
When did exclusivity expire and when could Mylan launch generics or authorized copies?
No FDA approval date, Orange Book exclusivity end date (or listed patents’ expiration dates), or settlement-driven launch date is included.
What is the timeline from filing to potential commercial entry?
Not provided.
Which patents blocked launch under the settlement or litigation stay?
Not provided.
How does Teva v. Mylan 1:17-cv-01790 affect the competitive landscape for the branded product?
No brand name, active ingredient, strength, approved label, or estimated revenue exposure is provided. Without those inputs, the competitive impact cannot be stated accurately.
Which other generic entrants were positioned to launch?
Not provided.
Did this case influence other Paragraph IV cases in the same patent family?
Not provided.
What regulatory pathway and FDA milestones were implicated by the litigation?
No FDA docket details are included: no ANDA number, filing date, acceptance date, tentative approval date, approval date, or exclusivity/Patent Listing status.
Was FDA approval stayed due to litigation under 21 U.S.C. § 355(j)(5)?
Not provided.
Was there a triggering event such as a final court decision or settlement?
Not provided.
Key Takeaways
- The provided docket reference (1:17-cv-01790) and case caption are insufficient to generate a complete litigation summary with accurate patent, FDA, and disposition facts.
- No asserted patents, court decisions, settlement terms, or launch implications are contained in the available inputs, so no reliable patent-strategy or regulatory analysis can be produced.
FAQs
-
What is docket 1:17-cv-01790’s final disposition?
Not provided.
-
Which Orange Book patents are listed for the Teva product at issue in 1:17-cv-01790?
Not provided.
-
Did Mylan file an ANDA with Paragraph IV certifications in this case?
Not provided.
-
Did the court issue a claim construction decision in 1:17-cv-01790?
Not provided.
-
What launch date, if any, was permitted under settlement or court rulings?
Not provided.
References
- Teva Pharmaceuticals International GmbH v. Mylan Laboratories Limited, 1:17-cv-01790 (U.S. District Court).
